Proximal myopathy: Diagnostic approach and initial management

Postgraduate Medical Journal

Volumn 89, Issue 1054, 2013, Pages 470-477

  Suresh, Ernest ^a   Wimalaratna, Sunil ^b  

^a ALEXANDRA HOSPITAL   (Singapore)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; CALCIUM ION; CREATINE KINASE; CYCLOPHOSPHAMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; LACTATE DEHYDROGENASE; METHOTREXATE; MYOGLOBIN; PREDNISOLONE; RITUXIMAB; THYROTROPIN;

ALCOHOL CONSUMPTION; CANCER SCREENING; CLINICAL FEATURE; DERMATOMYOSITIS; DIFFERENTIAL DIAGNOSIS; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; EXERCISE; FORCED VITAL CAPACITY; HUMAN; LIMB WEAKNESS; META ANALYSIS (TOPIC); MUSCLE BIOPSY; MUSCLE WEAKNESS; MYOSITIS; MYOTONIC DYSTROPHY; NEUROPHYSIOLOGY; OSTEOMALACIA; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR;

PROXIMAL MYOPATHY;

CREATINE KINASE; DIAGNOSIS, DIFFERENTIAL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUSCLES; MUSCULAR DISEASES; MYOSITIS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84880326963     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/postgradmedj-2013-131752     Document Type: Review

References (68)

1. Rendt K. Inflammatory myopathies: narrowing the differential diagnosis. Cleve Clin J Med 2001;68(6):505, 509-14, 517-519.
2. Clark JW. Clinical neurology: from the classroom to the exam room. 1st edn. Philadelphia: Lippincott Williams & Wilkins, 2007.
3. Mangera Z, Panesar G, Makker H. Practical approach to management of respiratory complications in neurological disorders. Int J Gen Med 2012;5:255-263.
4. Imbert-Masseau A, Hamidou M, Agard C, et al. Anti-synthetase syndrome. Joint Bone Spine 2003;70:161-168.
5. Soule BR, Simone NL. Hypokalemic periodic paralysis: a case report and review of the literature. Cases J 2008;1:256.
6. Dalakas MC. Toxic and drug-induced myopathies. J Neurol Neurosurg Psychiatry 2009;80:832-838.
7. Afifi AK, Bergman RA, Harvey JC. Steroid myopathy: clinical, histologic and cytologic observations. Johns Hopkins Med J 1968;123:158-173.
8. Kelly FJ, McGrath JA, Goldspink DF, et al. A morphological/biochemical study on the actions of corticosteroids on rat skeletal muscle. Muscle Nerve 1986;9:1-10.
9. Pereira RM, Freire de Carvalho J. Glucocorticoid-induced myopathy. Joint Bone Spine 2011;78:41-44.
10. Nichols GA, Koro CE. Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and non-diabetic patients. Clin Ther 2007;29:1761-1770.
11. Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high dose statin therapy in hyperlipidemic patients- the PRIMO study. Cardiovasc Drugs Ther 2005;19:403-414.
12. Fernandez G, Spatz ES, Jablecki C, et al. Statin myopathy: a common dilemma not reflected in clinical trials. Cleve Clin J Med 2011;78:393-403.
13. Gaist D, Rodriguez LA, Huerta C, et al. Lipid lowering drugs and myopathy: a population-based follow-up study. Epidemiology 2001;12:565-569.
14. Josan K, Majumdar SR, McAlister FA. The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. CMAJ 2008;178:576-584.
15. Kashani A, Phillips CO, Foody JM, et al. Risks associated with statin therapy: a systematic overview of randomised clinical trials. Circulation 2006;114:2788-2797.
16. Silva MA, Swanson AC, Gandhi PJ, et al. Statin-related adverse events: a meta-analysis. Clin Ther 2006;28:26-35.
17. Silva M, Matthews ML, Jarvis C, et al. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin Ther 2007;29:253-260.
18. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681-1690.
19. Martin F, Ward K, Slavin G, et al. Alcoholic skeletal myopathy: a clinical and pathological study. Q J Med 1985;55:233-251.
20. Urbano-Marquez A, Estruch R, Navarro-Lopez F, et al. The effects of alcoholism on skeletal and cardiac muscle. N Engl J Med 1989;320:409-415.
21. Smith DJ, Olive KE. Chinese red rice-induced myopathy. South Med J 2003;96:1265-1267.
22. Mueller PS. Symptomatic myopathy due to red yeast rice. Ann Intern Med 2006;145:474-475.
23. Fessel WJ. Myopathy of hypothyroidism. Ann Rheum Dis 1968;27:590-596.
24. Duyff RF, Van den Bosch J, Laman DM, et al. Neuromuscular findings in thyroid ysfunction: a prospective clinical and electrodiagnostic study. J Neurol Neurosurg Psychiatry 2000;68:750-755.
25. Rodolico C, Toscano A, Benvenga S, et al. Myopathy as the persistently isolated symptomatology of primary autoimmune hypothyroidism. Thyroid 1998;8:1033-1038.
26. Madhu SV, Jain R, Kant S, et al. Myopathy presenting as a sole manifestation of hypothyroidism. J Assoc Physicians India 2010;58:569-570.
27. Skaria J, Katiyar BC, Srivastava TP, et al. Myopathy and neuropathy associated with osteomalacia. Acta Neurol Scand 1975;51:37-58.
28. Schott GD, Wills MR. Muscle weakness in osteomalacia. Lancet 1976;1:626-629.
29. Irani PF. Electromyography in nutritional osteomalacic myopathy. J Neurol Neurosurg Psychiatry 1976;39:686-693.
30. Mastaglia FL, Phillips BA. Idiopathic inflammatory myopathies: epidemiology, classification and diagnostic criteria. Rheum Dis Clin North Am 2002;28:723-741.
31. Marie I, Hachulla E, Hatron PY, et al. Polymyositis and dermatomyositis: short term and long term outcome, and predictive factors of prognosis. J Rheumatol 2001;28:2230-2237.
32. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003;362:971-982.
33. Munshi SK, Thanvi B, Jonalagadda SJ, et al. Inclusion body myositis: an underdiagnosed myopathy of older people. Age Ageing 2006;35:91-94.
34. Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in polymyositis and dermatomyositis: a population based study. Lancet 2001;357:96-100.
35. Buchbinder R, Forbes A, Hall S, et al. Incidence of malignant disease in biopsy-proven inflammatory myopathy: a population based cohort study. Ann Intern Med 2001;134:1087-1095.
36. Liu WC, Ho M, Koh WP, et al. An 11-year review of Asian patients with dermatomyositis. Ann Acad Med Singapore 2010;39:843-847.
37. Emery AE. Muscular dystrophies. Lancet 2002;359:687-695.
38. Norwood FL, Harling C, Chinnery PF, et al. Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population. Brain 2009;132 (Part 11):3175-3186.
39. Das AM, Steuerwald U, Illsinger S. Inborn errors of energy metabolism associated with myopathies. J Biomed Biotechnol 2010;2010:340849.
40. Crum-Cianflone NF. Bacterial, fungal, parasitic and viral myositis. Clin Microbiol Rev
41. Fayad F, Liote F, Berenbaum F, et al. Muscle involvement in sarcoidosis: a retrospective and follow-up studies. J Rheumatol 2006;33:98-103.
42. Bohan A, Peter JB, Bowman RL, et al. A computer assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine 1977;56:255-286.
43. Rose MR, Kissel JT, Bickley LS, et al. Sustained myoglobinuria: the presenting manifestation of dermatomyositis. Neurology 1996;47:119-123.
44. Lacomis D. Electrodiagnostic approach to the patient with suspected myopathy. Neurol Clin 2012;30:641-660.
45. Goodwin DW. Imaging of skeletal muscle. Rheum Dis Clin North Am 2011;37:245-251.
46. Sparsa A, Liozon E, Herrmann F, et al. Routine versus extensive malignancy search or adult dermatomyositis and polymyositis: a study of 40 patients. Arch Dermatol 2002;138:885-980.
47. Till SH, Jones AC. Dermatomyositis- how far to go! Ann Rheum Dis 1998;57:198-200.
48. Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med 2009;150:858-868.
49. Selva-O'Callaghan A, Grau JM, Gamez-Cenzano C, et al. Conventional cancer screening versus PET/CT in dermatomyositis/polymyositis. Am J Med 2010;123:558-562.
50. Nasr R, Reed AM, Peterson EJ. Update: biomarkers for idiopathic inflammatory myopathies. Curr Opin Rheumatol 2012;24:609-615.
51. Matthews E, Hanna MG. Muscle channelopathies: does the predicted channel gating pore offer new treatment insights for hypokalemic periodic paralysis? J Physiol 2010;588(Part 11):1879-1886.
52. Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al. ACC/AHA/NHLBI Clinical advisory on the use and safety of statins. Circulation 2002;106:1024-1028.
53. McKenney JM, Davidson MH, Jacobson TA, et al. National Lipid Association Safety Assessment Task Force. Final conclusions and recommendations of the National Lipid Association Safety Assessment Task Force. Am J Cardiol 2006;97:89C-94C.
54. Smith CC, Bernstein LI, Davis RB, et al. Screening for statin-related toxicity: the yield of transaminase and creatine kinase measurements in a primary care setting. Arch Intern Med 2003;163:688-692.
55. Hansen KE, Hildebrand JP, Ferguson EE, et al. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med 2005;165:2671-2676.
56. Caso G, Kelly P, McNurian MA, et al. Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. Am J Cardiol 2007;99:1409-1412.
57. Ghirlanda G, Oradei A, Manto A, et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind placebo controlled study. J Clin Pharmacol 1993;33:226-269.
58. Cordeiro AC, Isenberg DA. Treatment of inflammatory myopathies. Postgrad Med J 2006;82:417-424.
59. Greenberg SA. Inflammatory myopathies: evaluation and management. Semin Neurol 2008;28:241-249.
60. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993;329:1993-2000.
61. Wang DX, Shu XM, Tian XL, et al. Intravenous immunoglobulin therapy in adult patients with polymyositis/dermatomyositis: a systematic literature review. Clin Rheumatol 2012;31:801-806.
62. Miller FW, Leitman SF, Cronin ME, et al. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med 1992;326:1380-1384.
63. Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005;52:601-607.
64. Noss EH, Hausner-Sypek DL, Weinblatt ME. Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol 2006;33:1021-1026.
65. Chung L, Genovese MC, Florentino DF. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 2007;143:763-767.
66. Habers GE, Takken T. Safety and exercise training in patients with an idiopathic inflammatory myopathy: a systematic review. Rheumatology (Oxford) 2011;50:2113-2124.
67. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy. Part 2: implementation of multidisciplinary care. Lancet Neurol 2010;9:177-189.
68. Mendell JR, Moxley RT, Griggs RC, et al. Randomised double-blind six month trial of prednisolone in Duchenne's muscular dystrophy. N Engl J Med 1989;320:1621-1623.